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2016; 9(10): [1524] [1525] [1526] [1527] DearEditor, W epresentacaseofdexamethasone(DEX)intravitreal implantation(Ozurdex 誖 ;Allergan,Irvine,CA, USA)totreatdiabeticmacularedema(DME)during pregnancy.AccordingtoPescosolido [1] ,pregnancymay promotetheonsetofdiabeticretinopathyinabout10%of casesandmaycontributetoitsworseningwhenalready present,causingmacularedema [1] .Althoughonereporthas indicatedthat DMEduringpregnancyspontaneously regressesafterdelivery [1] ,othershavereportedthatDMEcan persistandbeassociatedwithsevereandpersistentvisual dysfunction [2] .Treatmentofdiabeticretinopathyduring pregnancyislimited.TheNationalInstituteforClinical Excellenceguidelinesstatethatevidencesupportstheuseof lasertreatmentforDME [3] .Intravitrealinjectionsof anti-vascularendothelialgrowthfactor(anti-VEGF)suchas bevacizumabtowomenearlyinapregnancycanresultin miscarriage,althoughtheexactcause-and-effectrelationship isnotdemonstrated [4] [5] .Casesofpatientswhoweresuffering frompreeclampsiaandcaesareansectionwithpreterm deliveryhavebeenreported.Theinfantalsohasrespiratory distresssyndrome, pulmonaryhemorrhage,pulmonary stenosis,andintraventricularcerebralhemorrhage [6] .There hasbeenacasereportofasingleintravitrealinjectionof triamcinoloneacetonomidetotreatDMEinawomanwho was6mopregnant.TheresolutionofDMEandtheimproved visionpersistedthroughoutthepregnancywithoutfurther intervention [7] . TheOzurdex 誖 ,DEXintravitrealimplantisasustainedreleasebiodegradableimplantapprovedfortreatingmacular edemaduetoretinalveinocclusionordiabeticretinopathy. Thesafetyandtheeffectivenessofthisimplanthavebeen demonstratedinseveralstudies,includingareportofamean offourtofiveinjectionsover3ywithrobustlong-term improvementinvisionandresolutionofmacularedemain patientswithDME [8] . [9] .Vasculogenesisandangiogenesis,theformationof newbloodvesselsinthedevelopingembryo,occurduring thefirsttrimester.Duringthisperiod,VEGFfamilyandtheir receptorsareimportantgrowthfactors [10] .Vasculogenesisis alsomediatedbyVEGF-A.Therefore,anti-VEGFagents mayhaveharmfuleffectbothonthemotherandthefetus [11] . Anintravitrealanti-VEGFinjectionadministeredtoawoman earlyinpregnancyhas beenreportedtoresultin miscarriage [4] . Pre-eclampsia(hypertensionandproteinuriaduring pregnancy,usuallyinthethirdtrimester)maybea manifestationof inadequateangiogenicgrowthfactor activities.PharmacologicalinhibitionofVEGFdecreasethe levelsofcirculating angiogenicgrowthfactors,thus potentiallyincreasingtheriskofpre-eclampsia [12] .Astudy hassuggestedthatbothsystolicanddiastolicbloodpressures mayrise3wkafterasingle1.25mgbevacizumabintravitreal injection [13] . Previousstudieshaveshownthatthereareseveral advantagesofusingintravitrealcorticosteroidversus anti-VEGF.In terms ofsafety,anti-VEGFsuchas ranibizumabandbevacizumabisdesignatedasapregnancy categoryCdrug.However,corticosteroidisdesignatedas pregnancycategoryBdrug.Inaddition,multipleanti-VEGF injectionsare usuallynecessaryto treatDME.Thus, continuousinhibitionofVEGF-Afortreatingretinaldiseases canpotentiallyaffectthedevelopingembryoandthemother [12] . However,corticostereoidsuchasDEXimplantationis knowntobeeffectiveforupto6mowithasingleinjection. AccordingtoDegenringandJonas [14] ,afteranintravitreal high-doseinjectionof20to25mgtriamcinoloneacetonide, serumlevelsoftriamcinoloneacetonidedidnotdiffer significantlybetweenpreoperatively(0mcg/L)and postoperatively(0.065mcg/L).In90%eyes,triamcinolone acetonidecouldnotbedetectedinserumsamples.A pharmacokineticstudyofintravitreallyinjectedDEXin monkeyeyesalsohasshownthatDEXispresentonlyatlow concentrationsintheplasmaatanytimeafterimplanataion. After60dof0.7mgDEXimplantation,DEXisdetected 1110ng/ginretina,213ng/mLinvitreoushumorand 1.1ng/mLinserum [15] .Thus,wecouldexpectthatDEX couldgreatlyminimizeadverseeffectsassociatedwith systemicexposuretoglucocorticoids.Inaddition,DEX,a syntheticglucocorticoid,hasbeenusedtoacceleratefetal lungmaturation.Itissometimesusedclinicallyduring prematurelaborforthispurpose.Therefore,contraryto intravitreal anti-VEGFinjectionstopregnantwomen, prenatalsteroidsappeartoimprovethesurvivalofinfants andlimitbraininjuriestoinfants [8] . Also,resolutionofDME withoutharmfuleffectonpregnantwomanandherbabyhas beendescribedwithintravitrealinjectionoftriamcinolone acetonomide [7] .IntravitrealDEXimplantationhasbeen approvedastreatmentofmacularedema.Thus,DEXis probablysaferthantriamcinoloneacetonomide,anoff-label drug. OurpatientpresentedacaseofDMEinbotheyesduring week10ofanIUP.Nospontaneousresolutionor improvementof theDMEwasdetectedduringclose follow-up.Moreover,anabruptdecreaseinvisionwithVH andpersistentedemainherrighteyeatweek24IUP necessitatedtreatment.Althoughtherewereseveralcase reportsabouttheuseofintravitrealanti-VEGFinjections duringthethirdtrimesterwithoutcomplications [16] [17] , intravitrealDEXwasimplantedinherrighteye,considering therelativesafetyofintravitrealcorticosteroids [18] towarda fetuscomparedtobevacizumaborranibizumab [7] .This treatmentclearlyresolvedhermacularedemawithgood visualoutcomeandlong-termsafetywithoutcausingany apparentadversereactiononboththepatientandfetus. Inconclusion,weproposethatintravitrealDEXimplantation maybeasafeandeffectivetreatmentmodalityformanaging severeDMEasshowninthiscase,thatcausesdecreased visionwithoutspontaneousimprovementin pregnant women.Itshouldbeconsideredasatreatmentoptionfor thesepatients,butmorestudiesareneededtoproveits safety.
